Late-Onset Pompe Disease When Enzyme Replacement Therapy Has Not Achieved Motor or Respiratory Goals

Clinical Scenario

Late-onset Pompe disease presenting after the age of 1 year — in childhood or adulthood — with proximal (limb girdle) myopathy and progressive motor disability. Cardiac involvement is absent in this population.

Previous Treatment — Inadequate Response

This protocol applies when enzyme replacement therapy (ERT) with Alglucosidase alfa has not met the expected treatment goals: improvement in motor function as measured by the 6-minute walk test (6-MWT), or improvement in respiratory function as measured by forced vital capacity (FVC).

A suboptimal response, a plateau, or clinical decline on the standard dose defines the failure condition that indicates the need to reassess treatment.

Next-Step Approach

The structured protocol addresses a dose-escalation strategy using the same enzyme replacement agent for eligible late-onset patients who meet the failure criteria above — the full eligibility conditions, adjustment pathway, and decision algorithm are contained in the complete regimen.

Therapeutic goals: stabilization or improvement of skeletal muscle and respiratory function.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1186/s13023-024-03373-w

Patients may present at any age, but mostly after the age of 1 year during childhood or adulthood.

They usually present with proximal (limb girdle) myopathy leading to progressive motor disability (more closely related to disease duration than to the age of the patient), with waddling gait, mostly without cardiac involvement.

High-dose rhGAA may also be a treatment option for late-onset Pompe disease patients showing a suboptimal response, plateau, or clinical decline at the standard dose, in the absence of infusion-associated reactions and clinically significant anti-rhGAA neutralizing antibody titers, but further studies are needed to demonstrate this effect.

Dose may be increased up to 40 mg/kg/eow or 40 mg/kg/w in patients with classic infantile and in late onset patients showing a suboptimal response, plateau, or clinical decline.

View source ↗